Prognostic implications of decreased microRNA‑101‑3p expression in patients with non‑small cell lung cancer

Lu,Hai‑Min; Yi,Wan‑Wan; Ma,Yu‑Shui; Wu,Wei; Yu,Fei; Fan,Heng‑Wei; Lv,Zhong‑Wei; Yang,Hui‑Qiong; Chang,Zheng‑Yan; Zhang,Chao; Xie,Wen‑Ting; Jiang,Jun‑Jian; Song,Ying‑Chun; Chai,Li; Jia,Cheng‑You; Lu,Gai‑Xia; Zhong,Xiao‑Jun; Hou,Li‑Kun; Wu,Chun‑Yan; Shi,Min‑Xin; Liu,Ji‑Bin; Fu,Da

doi:10.3892/ol.2018.9559

Prognostic implications of decreased microRNA‑101‑3p expression in patients with non‑small cell lung cancer

Authors:
- Hai‑Min Lu
- Wan‑Wan Yi
- Yu‑Shui Ma
- Wei Wu
- Fei Yu
- Heng‑Wei Fan
- Zhong‑Wei Lv
- Hui‑Qiong Yang
- Zheng‑Yan Chang
- Chao Zhang
- Wen‑Ting Xie
- Jun‑Jian Jiang
- Ying‑Chun Song
- Li Chai
- Cheng‑You Jia
- Gai‑Xia Lu
- Xiao‑Jun Zhong
- Li‑Kun Hou
- Chun‑Yan Wu
- Min‑Xin Shi
- Ji‑Bin Liu
- Da Fu
View Affiliations

Affiliations: Department of Thoracic Surgery, Nantong Tumor Hospital, Nantong, Jiangsu 226631, P.R. China, Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, P.R. China, Department of Hepatic Surgery I, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, P.R. China, Department of Pathology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Department of Hand Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China, Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangsu 330006, P.R. China, Central Laboratory for Medical Research, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China
Published online on: October 9, 2018 https://doi.org/10.3892/ol.2018.9559
Pages: 7048-7056
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To investigate the expression level of microRNA‑101‑3p (miR‑101‑3p) and its possible association with progression, prognosis and chemotherapy in patients with non‑small cell lung cancer (NSCLC), the Gene Expression Omnibus (GEO) database was used. Quantitative polymerase chain reaction was used to verify the expression in 327 NSCLC and 42 adjacent normal lung tissues, of which 42 viable tissues were paired with nearby normal lung tissues. Based on the Cox regression model, univariate and multivariate analyses were used to address the factors that had effects on overall survival (OS) and disease‑free survival (DFS) rate. Data from the GEO database demonstrated that the miR‑101‑3p expression in NSCLC was downregulated, compared with normal lung cancer. Survival analysis through univariate and multivariate models indicated that the miR‑101‑3p expression level was a crucial risk factor for OS and DFS in patients with NSCLC. A number of clinical parameters were determined to be associated with miR‑101‑3p expression, including tumor diameter, lymph node metastasis and tumor‑node‑metastasis stage. Adjuvant chemotherapy with high expression of miR‑101‑3p was determined to increase OS and DFS in patients with NSCLC, compared with patients with de novo or low expression of miR‑101‑3p. The present results demonstrated that miR‑101‑3p expression levels were associated with NSCLC progression and prognosis, which indicated that miR‑101‑3p may serve as a biomarker for patients with NSCLC who have received adjuvant chemotherapy.

View Figures

View References

1	Lu G, Fu D, Jia C, Chai L, Han Y, Liu J, Wu T, Xie R, Chang Z, Yang H, et al: Reduced miR-105-1 levels are associated with poor survival of patients with non-small cell lung cancer. Oncol Lett. 14:7842–7848. 2017.PubMed/NCBI
2	Zhang T, Rong N, Chen J, Zou C, Jing H, Zhu X and Zhang W: SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC. PLoS One. 8:e791622013. View Article : Google Scholar : PubMed/NCBI
3	Hou L, Luo P, Ma Y, Jia C, Yu F, Lv Z, Wu C and Fu D: MicroRNA-125a-3p downregulation correlates with tumorigenesis and poor prognosis in patients with non-small cell lung cancer. Oncol Lett. 14:4441–4448. 2017. View Article : Google Scholar : PubMed/NCBI
4	Hou LK, Ma YS, Han Y, Lu GX, Luo P, Chang ZY, Xie RT, Yang HQ, Chai L, Cai MX, et al: Association of microRNA-33a molecular signature with non-small cell lung cancer diagnosis and prognosis after chemotherapy. PLoS One. 12:e01704312017. View Article : Google Scholar : PubMed/NCBI
5	Yu F, Liu JB, Wu ZJ, Xie WT, Zhong XJ, Hou LK, Wu W, Lu HM, Jiang XH, Jiang JJ, et al: Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14. Cancer Lett. 427:74–84. 2018. View Article : Google Scholar : PubMed/NCBI
6	Ma YS, Wu TM, Lv ZW, Lu GX, Cong XL, Xie RT, Yang HQ, Chang ZY, Sun R, Chai L, et al: High expression of miR-105-1 positively correlates with clinical prognosis of hepatocellular carcinoma by targeting oncogene NCOA1. Oncotarget. 8:11896–11905. 2017.PubMed/NCBI
7	Xu C, Haque F, Jasinski DL, Binzel DW, Shu D and Guo P: Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy. Cancer Lett. 414:57–70. 2018. View Article : Google Scholar : PubMed/NCBI
8	Salzman DW, Nakamura K, Nallur S, Dookwah MT, Metheetrairut C, Slack FJ and Weidhaas JB: miR-34 activity is modulated through 5′-end phosphorylation in response to DNA damage. Nat Commun. 7:109542016. View Article : Google Scholar : PubMed/NCBI
9	Persson H, Søkilde R, Häkkinen J, Pirona AC, Vallon-Christersson J, Kvist A, Mertens F, Borg Å, Mitelman F, Höglund M and Rovira C: Frequent miRNA-convergent fusion gene events in breast cancer. Nat Commun. 8:7882017. View Article : Google Scholar : PubMed/NCBI
10	Xie RT, Cong XL, Zhong XM, Luo P, Yang HQ, Lu GX, Luo P, Chang ZY, Sun R, Wu TM, et al: MicroRNA-33a downregulation is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma. Oncol Lett. 15:4571–4577. 2018.PubMed/NCBI
11	Mi Y, Zhang D, Jiang W, Weng J, Zhou C, Huang K, Tang H, Yu Y, Liu X, Cui W, et al: miR-181a-5p promotes the progression of gastric cancer via RASSF6-mediated MAPK signalling activation. Cancer Lett. 389:11–22. 2017. View Article : Google Scholar : PubMed/NCBI
12	Cutrona G, Matis S, Colombo M, Massucco C, Baio G, Valdora F, Emionite L, Fabris S, Recchia AG, Gentile M, et al: Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: Implication for therapy. Leukemia. 31:1894–1904. 2017. View Article : Google Scholar : PubMed/NCBI
13	Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA and Cullen BR: Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol. 84:11670–11678. 2010. View Article : Google Scholar : PubMed/NCBI
14	Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
15	Othman N and Nagoor NH: miR-608 regulates apoptosis in human lung adenocarcinoma via regulation of AKT2. Int J Oncol. 51:1757–1764. 2017. View Article : Google Scholar : PubMed/NCBI
16	Zhang X, He X, Liu Y, Zhang H, Chen H, Guo S and Liang Y: MiR-101-3p inhibits the growth and metastasis of non-small cell lung cancer through blocking PI3K/AKT signal pathway by targeting MALAT-1. Biomed Pharmacother. 93:1065–1073. 2017. View Article : Google Scholar : PubMed/NCBI
17	Wang H, Wang L, Zhang G, Lu C, Chu H, Yang R and Zhao G: MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. Oncotarget. 9:7501–7512. 2017.PubMed/NCBI
18	Liu C, Fu H, Liu X, Lei Q, Zhang Y, She X, Liu Q, Liu Q, Sun Y, Li G and Wu M: LINC00470 coordinates the epigenetic regulation of ELFN2 to distract GBM cell autophagy. Mol Ther. 26:2267–2281. 2018. View Article : Google Scholar : PubMed/NCBI
19	Wakasugi H, Takahashi H, Niinuma T, Kitajima H, Oikawa R, Matsumoto N, Takeba Y, Otsubo T, Takagi M, Ariizumi Y, et al: Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment. Cancer Lett. 434:91–100. 2018. View Article : Google Scholar : PubMed/NCBI
20	Cao L, Chen Y, Zhang M, Xu DQ, Liu Y, Liu T, Liu SX and Wang P: Identification of hub genes and potential molecular mechanisms in gastric cancer by integrated bioinformatics analysis. PeerJ. 6:e51802018. View Article : Google Scholar : PubMed/NCBI
21	Keller A, Leidinger P, Vogel B, Backes C, ElSharawy A, Galata V, Mueller SC, Marquart S, Schrauder MG, Strick R, et al: miRNAs can be generally associated with human pathologies as exemplified for miR-144. BMC Med. 12:2242014. View Article : Google Scholar : PubMed/NCBI
22	Leidinger P, Brefort T, Backes C, Krapp M, Galata V, Beier M, Kohlhaas J, Huwer H, Meese E and Keller A: High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer. Oncotarget. 7:4611–4623. 2016. View Article : Google Scholar : PubMed/NCBI
23	Fujita Y, Yagishita S, Hagiwara K, Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Tsuta K, Nokihara H, Tamura T, et al: The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol Ther. 23:717–727. 2015. View Article : Google Scholar : PubMed/NCBI
24	Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta (T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Liang Z, Kong R, He Z, Lin LY, Qin SS, Chen CY, Xie ZQ, Yu F, Sun GQ, Li CG, et al: High expression of miR-493-5p positively correlates with clinical prognosis of non small cell lung cancer by targeting oncogene ITGB1. Oncotarget. 8:47389–47399. 2017.PubMed/NCBI
27	Zhang B, Fu D, Xu Q, Cong X, Wu C, Zhong X, Ma Y, Lv Z, Chen F, Han L, et al: The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1. Nat Commun. 9:17232018. View Article : Google Scholar : PubMed/NCBI
28	Huang Q, Zhang XW, Ma YS, Lu GX, Xie RT, Yang HQ, Lv ZW, Zhong XM, Liu T, Huang SX, et al: Up-regulated microRNA-299 corrected with poor prognosis of glioblastoma multiforme patients by targeting ELL2. Jpn J Clin Oncol. 47:590–596. 2017. View Article : Google Scholar : PubMed/NCBI
29	Chang TH, Tsai MF, Gow CH, Wu SG, Liu YN, Chang YL, Yu SL, Tsai HC, Lin SW, Chen YW, et al: Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C. Cancer Lett. 402:190–202. 2017. View Article : Google Scholar : PubMed/NCBI
30	Zheng HB, Zheng XG and Liu BP: miRNA-101 inhibits ovarian cancer cells proliferation and invasion by down-regulating expression of SOCS-2. Int J Clin Exp Med. 8:20263–20270. 2015.PubMed/NCBI
31	Tsai CH, Yang DY, Lin CY, Chen TM, Tang CH and Huang YL: Sphingosine-1-phosphate suppresses chondrosarcoma metastasis by upregulation of tissue inhibitor of metalloproteinase 3 through suppressing miR-101 expression. Mol Oncol. 11:1380–1398. 2017. View Article : Google Scholar : PubMed/NCBI
32	Wang C, Lu S, Jiang J, Jia X, Dong X and Bu P: Hsa-microRNA-101 suppresses migration and invasion by targeting Rac1 in thyroid cancer cells. Oncol Lett. 8:1815–1821. 2014. View Article : Google Scholar : PubMed/NCBI
33	Li JT, Jia LT, Liu NN, Zhu XS, Liu QQ, Wang XL, Yu F, Liu YL, Yang AG and Gao CF: MiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7. Oncotarget. 6:30818–30830. 2015.PubMed/NCBI
34	Shaker O, Alhelf M, Morcos G and Elsharkawy AL: miRNA-101-1 and miRNA-221 expressions and their polymorphisms as biomarkers for early diagnosis of hepatocellular carcinoma. Infect Genet Evol. 51:173–181. 2017. View Article : Google Scholar : PubMed/NCBI
35	Lv P, Zhang P, Li X and Chen Y: Micro ribonucleic acid (RNA)-101 inhibits cell proliferation and invasion of lung cancer by regulating cyclooxygenase-2. Thorac Cancer. 6:778–784. 2015. View Article : Google Scholar : PubMed/NCBI
36	Lei YM, Zu YF, Wang J, Bai S, Shi YF, Shi R, Duan J, Cui D, Chen J, Xiang Y and Dong J: Interleukin-1β-mediated suppression of microRNA-101 and upregulation of enhancer of zeste homolog 2 is involved in particle-induced lung cancer. Med Oncol. 32:3872015. View Article : Google Scholar : PubMed/NCBI
37	Wan X, Kong Z, Chu K, Yi C, Hu J, Qin R, Zhao C, Fu F, Wu H, Li Y and Huang Y: Co-expression analysis revealed PTCH1-3′UTR promoted cell migration and invasion by activating miR-101-3p/SLC39A6 axis in non-small cell lung cancer: Implicating the novel function of PTCH1. Oncotarget. 9:4798–4813. 2017.PubMed/NCBI
38	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI